点阵二氧化碳激光治疗绝经后阴道症状的随机假对照试验
该双盲随机假对照试验在澳大利亚悉尼单中心纳入85名有阴道症状的绝经后女性,比较三次点阵二氧化碳激光与假治疗的效果,随访12个月。结果显示两组在症状严重程度、生活质量和阴道健康指数上均无显著差异,激光未显著改善阴道症状。
要点
- 点阵二氧化碳激光治疗12个月未显著改善绝经后阴道症状。
- 激光组与假组在生活质量、阴道健康指数和组织学上无显著差异。
- 两组不良事件相似,均无严重不良事件报告。
核心结论
- 在有绝经后阴道症状的女性中,点阵二氧化碳激光与假治疗相比,12个月后未显著改善阴道症状。
研究设计与样本
- 双盲、随机、假对照试验,在澳大利亚悉尼单中心开展,随访12个月。
- 232名参与者被接触,最终85名绝经后阴道症状女性随机分组,激光组43人、假组42人。
- 干预为三次点阵微剥脱二氧化碳激光系统治疗,间隔4至8周。
主要发现
- 从基线到12个月,总体阴道症状VAS评分变化激光组-17.2 vs 假组-26.6,差异9.4(95%CI -28.6至47.5)。
- 最严重症状VAS评分变化激光组-24.5 vs 假组-20.4,差异-4.1(95%CI -32.5至24.3)。
- VSQ评分变化激光组-3.1 vs 假组-1.6,差异-1.5(95%CI -5.9至3.0)。
- 生活质量评分变化激光组6.3 vs 假组1.4,差异4.8(95%CI -3.9至13.5)。
- 阴道健康指数评分变化激光组0.9 vs 假组1.3,差异-0.4(95%CI -4.3至3.6)。
关键数值与推荐
- 共同主要结局为12个月时VAS(范围0-100)和VSQ(范围0-20)评估的症状严重程度。
- 最小临床重要差异设定为VAS和VSQ严重程度评分均下降50%。
临床怎么用
- 对于绝经后阴道症状,点阵二氧化碳激光不应被视为经证实有效的治疗选择。
- 临床决策应基于证据,优先考虑其他有证据支持的干预措施。
局限性
- 研究为单中心试验,样本量较小(85人随机)。
- 随访12个月,长期疗效未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Postmenopausal vaginal symptoms are common and frequently detrimental to a woman's quality of life. Fractional carbon dioxide vaginal laser is increasingly offered as a treatment, but the efficacy remains unproven. OBJECTIVE: To determine the efficacy of fractional carbon dioxide laser for treatment of vaginal symptoms associated with menopause. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, sham-controlled trial with 12-month follow-up was undertaken at a single tertiary referral hospital in Sydney, Australia. Enrollment commenced on September 19, 2016, with final follow-up on June 30, 2020. Participants were postmenopausal women with vaginal symptoms substantive enough to seek medical treatment. Of 232 participants approached, 85 were randomized. INTERVENTIONS: Three treatments using a fractional microablative carbon dioxide laser system performed 4 to 8 weeks apart, with 43 women randomized to the laser group and 42 to the sham group. MAIN OUTCOMES AND MEASURES: The co-primary outcomes were symptom severity assessed using a visual analog scale (VAS; range, 0-100; 0 indicates no symptoms and 100 indicates the most severe symptoms) and the Vulvovaginal Symptom Questionnaire (VSQ; range, 0-20; 0 indicates no symptoms and 20 indicates the most severe symptoms) at 12 months. The minimal clinically important difference was specified as a 50% decrease in both VAS and VSQ severity scores. There were 5 prespecified secondary outcomes, including quality of life (range, 0-100; higher scores indicate better quality of life), the Vaginal Health Index Score (range, 5-25; higher scores indicate better health), and vaginal histology (premenopausal or postmenopausal status). RESULTS: Of 85 randomized participants (mean [SD] age, 57 [8] years), 78 (91.7%) completed the 12-month follow-up. From baseline to 12 months, there was no significant difference between the carbon dioxide laser group and the sham group in change in symptom severity (VAS score for overall vaginal symptoms: -17.2 vs -26.6; difference, 9.4 [95% CI, -28.6 to 47.5]; VAS score for the most severe symptom: -24.5 vs -20.4; difference -4.1 [95% CI, -32.5 to 24.3]; VSQ score: -3.1 vs -1.6; difference, -1.5 [95% CI, -5.9 to 3.0]). There were no significant differences between the laser and sham group in the mean quality of life score (6.3 vs 1.4; difference, 4.8 [95% CI, -3.9 to 13.5]) and Vaginal Health Index Score (0.9 vs 1.3; difference, -0.4 [95% CI, -4.3 to 3.6]) or in histological comparisons between laser and sham treatment groups. There were 16 adverse events in the laser group and 17 in the sham group, including vaginal pain/discomfort (44% vs 68%), spotting, discharge, and lower urinary tract symptoms. No severe adverse events were reported in either group. CONCLUSIONS AND RELEVANCE: Among women with postmenopausal vaginal symptoms, treatment with fractional carbon dioxide laser vs sham treatment did not significantly improve vaginal symptoms after 12 months. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry: ACTRN12616001403426.
引用
- Li FG, Maheux-Lacroix S, Deans R, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA. 2021. PMID: 34636862. doi:10.1001/jama.2021.14892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。